TOURETTE SYNDROME TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-105913 | Health Care
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Tourette Syndrome Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL TOURETTE SYNDROME TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL TOURETTE SYNDROME TREATMENT MARKET
7.1 GLOBAL TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA TOURETTE SYNDROME TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Neurocrine Biosciences, Inc. (United States)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Novartis AG (Switzerland)
16.3 Otsuka Pharmaceutical Co., Ltd. (Japan)
16.4 Teva Pharmaceuticals USA, Inc. (Israel)
16.5 Apotex, Inc. (Canada)
16.6 Janssen Pharmaceuticals, Inc. (Belgium)
16.7 Zydus Pharmaceuticals USA, Inc. (India)
16.8 Eli Lilly (United States)
16.9 Torrent Pharmaceuticals Limited. (United States)
16.10 Boehringer Ingelheim (Germany)
16.11 Sandoz (Germany)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TreatmentMedication
Therapy
By Distribution Channel
Online
Offline
By Medication
Botulinum (Botox) injections
ADHD medications
Central adrenergic inhibitors
Antidepressants
Antiseizure medications
By Tics type
Motor Tics (Simple tics Complex tics)
Vocal Tics (Simple tics Complex tics)
Others
By End User
Infants
Older teenage
Adult patients
Companies
Neurocrine Biosciences, Inc. (United States)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceuticals USA, Inc. (Israel)
Apotex, Inc. (Canada)
Janssen Pharmaceuticals, Inc. (Belgium)
Zydus Pharmaceuticals USA, Inc. (India)
Eli Lilly (United States)
Torrent Pharmaceuticals Limited. (United States)
Boehringer Ingelheim (Germany)
Sandoz (Germany)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.